Photocure ASA - Cevira Study completes study enrolment on time
Cevira study completes study enrolment on time First study to evaluate optimal dose of novel integrated drug-delivery device. First novel therapeutic treatment option for highly prevalent cervical human papillomavirus (HPV) infections and precancerous lesions [] Oslo, Norway, January 3, 2012: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, has completed patient enrolment in the phase IIb dose-finding study for Cevira - the first trial to evaluate the optimal dose of the novel integrated intravaginal drug-